• Inotuzumab ozogamicin is available as a powder for reconstitution. It should be mixed with sterile water for injection and diluted with 0.9% sodium chloride with only gentle inversion without shaking.
• The diluted solution should be inspected for the presence of any visible particles or any discoloration before administration and should be discarded if present.
• The refrigerated diluted solution should be allowed to come at room temperature for about 1 hour before administration.
• The injection is given intravenously (directly into the vein) using a separate intravenous line by a healthcare provider in a hospital setting.
• Premedication with antipyretic (fever reducing), antihistamine (anti-allergy) and corticosteroids are recommended before starting the treatment to minimize or avoid infusion-related infusions.
• The subsequent cycles of Inotuzumab ozogamicin are for four weeks duration.
• The treatment should be discontinued in patients who do not respond to three cycles of treatment.
• Patients who proceed to hematopoietic stem cell transplant (HSCT) should receive only 2 cycles of treatment.
• Patients who do not proceed to hematopoietic stem cell transplant (HSCT) can receive a maximum of 6 cycles.
• Allergy to inotuzumab ozogamicin
• Pregnancy and breastfeeding
• Severe liver disorder
• Individuals predisposed to a type of cardiac rhythm problem called prolonged QTc interval
• Children below 18 years of age
• The diluted solution should be inspected for the presence of any visible particles or any discoloration before administration and should be discarded if present.
• The refrigerated diluted solution should be allowed to come at room temperature for about 1 hour before administration.
• The injection is given intravenously (directly into the vein) using a separate intravenous line by a healthcare provider in a hospital setting.
• Premedication with antipyretic (fever reducing), antihistamine (anti-allergy) and corticosteroids are recommended before starting the treatment to minimize or avoid infusion-related infusions.
Dosage & When it is to be taken
• The maximum recommended dose of inotuzumab ozogamicin (1.8 mg/m2) for the first cycle is given over a maximum period of 3 to 4 weeks (21 or 28-day cycle) in three divided doses on day 1, 8 and 15 or as exactly advised by the physician.• The subsequent cycles of Inotuzumab ozogamicin are for four weeks duration.
• The treatment should be discontinued in patients who do not respond to three cycles of treatment.
• Patients who proceed to hematopoietic stem cell transplant (HSCT) should receive only 2 cycles of treatment.
• Patients who do not proceed to hematopoietic stem cell transplant (HSCT) can receive a maximum of 6 cycles.
When it is not to be taken (Contraindications)
Inotuzumab ozogamicin should not be used in patients with• Allergy to inotuzumab ozogamicin
• Pregnancy and breastfeeding
• Severe liver disorder
• Individuals predisposed to a type of cardiac rhythm problem called prolonged QTc interval
• Children below 18 years of age
